Salicin-D-Salicin-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESalicinCat. No.: HY-N0149CAS No.: 138-52-3Synonyms: D-()-Salicin; Salicoside分式: CHO分量: 286.28作靶点: COX作通路: Immunology/Inflammation储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 150 mg/mL (5

2、23.96 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 3.4931 mL 17.4654 mL 34.9308 mL5 mM 0.6986 mL 3.4931 mL 6.9862 mL10 mM 0.3493 mL 1.7465 mL 3.4931 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Salicin个天然的 COX 抑制剂。IC50 & Target COX体外研究Sig

3、nificant down regulation of PGE2, the enzymatic product of COX2, to 76% in lysate and 70% insupernatant is observed with Salicin 10 M treatment in COLO cells when compare to the COLO control.1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEThis is accompanied with a minimal COX1 inhibition to 91% of

4、 the CCD control on the genetic level.Treatment with Salicin 1 M decreases colon cancer cell proliferation rates from 144% to 113% at 24 hoursand 187% to 130% at 48 hours, with 10 M decreasing proliferation rates to108% at 24 hours and 119% at48 hours 1. The concentrations of TNF-, IL-1 and IL-6 of

5、LPS-induced cells pretreated with 0.07, 0.14 and0.28 M Salicin are significant reduced compare with LPS group 2.体内研究 Salicin (D(-)-Salicin) (35, 70, 140 M) markedly inhibits the LPS-induced pathological changes. MPO activityin LPS-induced lung tissue is significantly increased compare with control g

6、roup. However, Salicin (35, 70,140 M) markedly inhibits this change. Pretreatment with Salicin inhibits LPS-induced activation of JNK,ERK, p38/MAPK and p65 in a dose-dependent manner 2.PROTOCOLCell Assay 2 RAW264.7 mouse macrophage cell line is used in this study. RAW264.7 cells are mechanically scr

7、aped andplated at a density of 4105 cells/mL onto 96-well plates in a 37C, 5% CO2 incubator for 1 h. Then the cellsare treated with 50 L Salicin (D(-)-Salicin) of different concentrations (0 to 0.28 M) for 1 h, followed bystimulation with 50 L Lipopolysaccharide (LPS) (4 g/mL). After 18 h, 10 L CCK-

8、8 is added to each welland continued to incubate for 4 h. Then, the optical density is measured at 450 nm on a microplate reader2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice are randomly divided into five groups, each containing three mi

9、ce: Control, Lipopolysaccharide (LPS)Administration 2 only, LPS+Salicin (D(-)-Salicin) group is injected intraperitoneally with Salicin 35 M, LPS+Salicin group isinjected intraperitoneally with Salicin 70 M, LPS+Salicin group is injected intraperitoneally with Salicin 140 M. After 1 h, 10 g LPS diss

10、olved in 50 L PBS is instilled intranasally to induce lung injury. Control mice aregiven 50 L PBS without LPS. After 12 h LPS treatment, bronchoalveolar lavage fluid (BALF) is collected 3times through a tracheal cannula with autoclaved PBS. Then, the tissue sample is centrifuged at 3000 rpm,for 10 m

11、in at 4C 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Jun Yan He, et al. Salicin as a Multipurpose Therapeutic Approach for Colon Cancer.2. Li Y, et al. D(-)-Salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models. Int Immunopharmacol. 2015Jun;26(2):286-94.McePdfHeightCaution: Product has no